In recent developments, Anavex announced promising results from an extension study of their
investigational drug, Anavex 2-73 (blarcamesine), for treating Parkinson’s
disease dementia. The study revealed that the therapy significantly reduced
symptom severity over a one-year period.
The extension study followed a Phase 2 clinical trial, known as ANAVEX 2-73-PDD-001, which included
132 participants. These patients initially displayed improvements in cognitive
abilities and motor functions when treated with Anavex 2-73. However, a “drug holiday”
period between the original trial and the extension study saw a regression in
symptoms, highlighting the necessity of continuous treatment.
When the extension study commenced, 20 participants resumed daily doses of Anavex 2-73. The
results were remarkable: average scores on the Movement Disorder
Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) improved,
indicating a reduction in motor and non-motor symptoms. The findings also
suggested overall better health and slower cognitive decline among the participants.
Christopher Missling, PhD, president and CEO of Anavex
Life Sciences, emphasized the potential impact of Anavex 2-73 on Parkinson’s disease treatment.
“This data suggests Anavex 2-73’s capability to slow and potentially
reverse the life-altering symptoms of Parkinson’s disease,” Missling stated.
The therapy was well-tolerated among participants, with a safety profile consistent with
previous studies. Encouraged by these findings, Anavex Life Sciences plans to
initiate a Phase 3 clinical trial. The primary goal will be to determine
whether six months of treatment can significantly improve MDS-UPDRS scores,
focusing on motor and daily activity impacts.
Participants from the extension study expressed interest in continuing the treatment under a
compassionate use special access scheme, with some already surpassing two years
of therapy. This ongoing commitment underscores the hope and optimism
surrounding Anavex 2-73 as a potential long-term treatment for Parkinson’s
disease dementia. See related link for additional information.
Find more information about Anavex Life Sciences on https://www.bloomberg.com/profile/company/AVXL:US